Comparative Pharmacology
Head-to-head clinical analysis: MARLISSA versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARLISSA versus NORINYL 1 80 21 DAY.
MARLISSA vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
MARLISSA 20 mg orally once daily with or without food.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated.
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive